Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: Successful engraftment and mild GVHD

Department of Hematology, The First Affiliated Hospital, Chinese PLA General Hospital, Beijing 100048, China.
Stem Cell Research (Impact Factor: 3.69). 10/2013; 12(1):132-138. DOI: 10.1016/j.scr.2013.10.001
Source: PubMed


Haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) is associated with an increased risk of graft failure and severe graft-versus-host disease (GVHD). Mesenchymal stromal cells (MSCs) have been shown to support in vivo normal hematopoiesis and to display potent immunesuppressive effects. We cotransplanted the culture-expanded third-party donor-derived umbilical cord MSCs (UC-MSCs) in 21 young people with severe aplastic anemia (SAA) undergoing haplo-HSCT without T-cell-depleted. We observed that all patients had sustained hematopoietic engraftment without any adverse UC-MSC infusion-related events. Furthermore, we did not observe any increase in severe aGVHD. These data suggest that UC-MSCs, possibly thanks to their potent immunosuppressive effect on allo-reactive host T lymphocytes escaping the preparative regimen, reduce the risk of graft failure and severe GVHD in haplo-HSCT.

8 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The immune response to infection is a rapid and multifaceted process. Infection affects homeostasis within the hematopoietic stem cell (HSC) niche, as lost immune cells must be replaced by HSCs. During the immune response, interferon is produced. Surprisingly, HSCs respond directly to interferon, entering the cell cycle from even the most dormant state. The complex response of both the HSCs and the niche to infection is a unique platform on which to consider HSC–niche interactions. Here, we comment on the contribution of the immune system to the niche and on the direct and indirect effect that infection has on HSCs in the niche.
    Annals of the New York Academy of Sciences 03/2014; 1310(1). DOI:10.1111/nyas.12400 · 4.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy and safety of cotransplantation of human umbilical cord mesenchymal stem cells (UC-MSCs) and haploidentical hematopoietic stem cells (HSCs) and to determine the correlation factors affecting incidence of graft versus host disease (GVHD) in patients with severe aplastic anemia (SAA), twenty-four SAA patients received haploidentical HSCs and UC-MSCs co-transplantation. Grafts came from a combination of granulocyte colony stimulating factor (G-CSF)-primed bone marrow and G-CSF mobilized peripheral blood stem cell of haploidentical donors, and in vitro expanded third-party donor derived UC-MSCs were employed as the cell graft. The conditioning regimens consisted of rabbit anti-human T-lymphocyte immunoglobulin (ATG), cyclophosphamide and fludarabine with or without busulfan. GVHD was prevented by using cyclosporine A (CSA), ATG, anti-CD25 monoclonal antibody and mycophenolate mofetil. All 24 patients achieved hematopoietic reconstitution. Median time to absolute neutrophil count >2 × 10(9)/L and platelet count >20 × 10(9)/L were 11 and 13 days, respectively. An incidence of 25 % on grade I-II acute GVHD was found while an incidence of 25 % of grade III-IV acute GVHD was seen. Blood type (r = 0.152, P = 0.043) and patient/donor pair (r = 0.541, P = 0.022) were significantly correlated with incidence of cGVHD. Transplantation related mortality was observed in 20.8 % of the cases. Co-transplantation of haploidentical HSCs and hUC-MSCs on SAA was an effective and safe approach in reducing GVHD and transplantation related mortality. The adequate conditioning regimen and early treatment for infection also played a critical role in the success of HSCT.
    Cytotechnology 11/2014; DOI:10.1007/s10616-014-9793-1 · 1.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Umbilical Cord Mesenchymal Stem Cells (UC-MSC) show properties similar to Bone Marrow Mesenchymal Stem Cells (BM-MSC), though controversial data exists regarding their osteogenic potential. We prepared clinical-grade UC-MSC from Wharton's Jelly and we investigated if UC-MSC could be used as substitutes for BM-MSC in muscoloskeletal regeneration as a more readily available and functional source of MSCs. UC-MSC were loaded onto scaffolds and implanted subcutaneously (ectopically) and in critical-size calvarial defects (orthotopically) in mice. For live cell-tracking experiments, UC-MSC were first transduced with the luciferase gene. Angiogenic properties of UC-MSC were tested using the mouse metatarsal angiogenesis assay. Cell secretomes were screened for the presence of various cytokines using an array assay. Analysis of implanted scaffolds showed that UC-MSC, contrary to BM-MSC, remained detectable in the implants for 3 weeks at most and did not induce bone formation in an ectopic location. Instead, they induced a significant increase of blood vessel ingrowth. In agreement with these observations, UC-MSC conditioned medium presented a distinct and stronger pro-inflammatory/chemotactic cytokine profile than BM-MSC and a significantly enhanced angiogenic activity. When UC-MSC were orthotopically transplanted in a calvarial defect, they promoted increased bone formation as well as BM-MSC. However, at variance with BM-MSC, the new bone was deposited through the activity of stimulated host cells highlighting the importance of the microenvironment on determining cell commitment and response. Therefore, we propose, as therapy for bone lesions, the use of allogeneic UC-MSC not depositing directly bone matrix, but acting through the activation of endogenous repair mechanisms.
    Stem Cells and Development 02/2015; 24(13). DOI:10.1089/scd.2014.0490 · 3.73 Impact Factor
Show more

Preview (2 Sources)

8 Reads
Available from